These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 208024)

  • 1. [Treatment of hyperlipemia with tibric acid (TA)].
    De Rosa L; Giangrandi E; Murante N; Scaroina F
    Minerva Med; 1978 Jun; 69(28):1917-22. PubMed ID: 208024
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
    Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of hyperlipemia and hyperuricemia with a combination of clofibrate and an extractive mucopolysaccharide complex].
    Loizzi P; Terlizzi N
    Reumatismo; 1975; 27(1):157-62. PubMed ID: 184507
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hypertriglyceridemia with tibric acid and clofibrate. Cross-over studies, effects on lipoproteins and absence of post-drug rebound.
    Smith FR; Noble RP; Goodman DS
    Atherosclerosis; 1978 Mar; 29(3):345-54. PubMed ID: 666884
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of tibric acid (CP-18.254) on plasma lipids in patients with primary endogenous hyperlipoproteinemia].
    Lisch HJ; Sailer S; Braunsteiner H
    Arzneimittelforschung; 1977; 27(10):2017-20. PubMed ID: 579116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response to tibric acid: a new hypolipidemic drug in type IV hyperlipoproteinemia.
    Bielmann P; Brun D; Moorjani S; Gagné C; Lupien P; Tétreault L
    Clin Pharmacol Ther; 1975 May; 17(5):606-11. PubMed ID: 165029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
    Gustafson A
    Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of type IV and V hyperlipemia--personal experiences].
    Sznajderman M
    Pol Arch Med Wewn; 1978 Feb; 59(2):161-9. PubMed ID: 205844
    [No Abstract]   [Full Text] [Related]  

  • 9. Altering lipid patterns in adult males.
    Appelbaum JJ; Amundsen MA; Perkin DK
    J Occup Med; 1974 Aug; 16(8):539-42. PubMed ID: 4367267
    [No Abstract]   [Full Text] [Related]  

  • 10. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM; Levy RI
    Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical trial of tibric acid, a new hypolipidemic agent].
    Noseda G; Sirtori CR
    Schweiz Med Wochenschr; 1974 Dec; 104(51):1917-22. PubMed ID: 4438990
    [No Abstract]   [Full Text] [Related]  

  • 12. The hypotriglyceridemic effect of chenodeoxycholic acid in type IV hyperlipemia.
    Camarri E; Marcolongo R; Zaccherotti L; Marini G
    Biomedicine; 1978 Oct; 29(6):193-8. PubMed ID: 216433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug therapy of hyperlipidemias].
    Wolfram G
    Wien Med Wochenschr; 1981; 131(13-14):333-8. PubMed ID: 7281700
    [No Abstract]   [Full Text] [Related]  

  • 14. A physician's guide to hyperlipidemia.
    Fredrickson DS
    Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative treatment of hyperlipoproteinaemias in chimpanzees.
    Vastesaeger M; Blaton V; Declercq B; Vercruysse J; Vandamme D; Peeters H; Mortelmans J
    Acta Zool Pathol Antverp; 1974; 58(0):79-96. PubMed ID: 4365833
    [No Abstract]   [Full Text] [Related]  

  • 16. Familial lipoatrophic diabetes with dominant transmission. A new syndrome.
    Dunnigan MG; Cochrane MA; Kelly A; Scott JW
    Q J Med; 1974 Jan; 43(169):33-48. PubMed ID: 4362786
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical and therapeutic evaluation of a new antilipemic substance].
    de Aguiar Magano L
    Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Type V hyperlipemia. 54 cases (author's transl)].
    Schlesinger M; Jacotot B; Beaumont V; Buxtorf JC
    Nouv Presse Med; 1979 Mar; 8(11):833-7. PubMed ID: 221880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
    Wolfe BM; Kane JP; Havel RJ; Brewster HP
    J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
    Arntz HR; Klemens UH; Vollmar LJ; Lang PD
    Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.